

## SLE Cumulative Damage Index Carolina Lupus Study Follow-Up 2001

The total damage in a patient with SLE may result from SLE itself or from any other pathologic process such as atherosclerosis, hypercoagulability, hypertension, therapy for SLE and other comorbid conditions. This global **Damage Index** summarizes the total of all damage that has occurred from any mechanism. Damage is defined as non-reversible change, not related to active inflammation, occurring since diagnosis of lupus, ascertained by clinical assessment and present for at least 6 months (unless otherwise stated).

Patient's Name:

DOB: «scr\_birth\_date»

Doctor's Name: **Dr. «fname» «referral\_text»**

Doctor ID: «ref\_source»

Date of Last Office Visit:  /  /   
(month) (day) (year)

Patient's Current Weight:      
pounds (If current weight not available, check (☐) here )

Date Completed:  /  /   
(month) (day) (year)

**Ocular** -- (either eye, by clinical assessment)

(Please circle only one response)

- |  |    |     |                    |                          |
|--|----|-----|--------------------|--------------------------|
| 1. <u>Cataract</u> (lens opacity), documented by ophthalmoscopy  | No | Yes | DK<br>(Don't Know) | <input type="checkbox"/> |
| 2. <u>Retinal change</u> or <u>optic atrophy</u> , documented by ophthalmoscopic exam -- may result in field defect, legal blindness | No | Yes | DK                 | <input type="checkbox"/> |

**Neuropsychiatric**

- |   |    |     |        |                          |
|---|----|-----|--------|--------------------------|
| 3. <u>Cognitive impairment</u> (memory deficit, difficulty with calculation, poor concentration, difficulty in spoken or written language, impaired performance level -- documented by clinical exam or by formal neurocognitive testing) OR <u>major psychosis</u> (altered ability to function in normal activity due to psychiatric reasons. Severe disturbance in the perception of reality characterized by delusions, hallucinations (auditory, visual), incoherence, marked loose associations, impoverished thought content, marked illogical thinking, bizarre, disorganized or catatonic behavior.) | No | Yes | DK     | <input type="checkbox"/> |
| 4. <u>Seizures</u> requiring therapy for <u>6 months</u> (paroxysmal electrical discharge occurring in the brain and producing characteristic physical changes including tonic and clonic movements and certain behavioral disorder)  | No | Yes | DK     | <input type="checkbox"/> |
| 5. <u>Cerebral vascular accident</u> , resulting in focal findings such as paresis, weakness, etc. OR surgical resection for causes other than malignancy   | 0  | 1   | *2+ DK | <input type="checkbox"/> |
| 6. <u>Cranial or peripheral neuropathy</u> (damage to either a cranial or peripheral nerve, excluding optic nerve, resulting in either motor or sensory dysfunction)  | No | Yes | DK     | <input type="checkbox"/> |
| 7. <u>Transverse myelitis</u> (lower-extremity weakness or sensory loss with loss of rectal and urinary bladder sphincter control)  | No | Yes | DK     | <input type="checkbox"/> |

**Renal**

- |   |    |     |    |                          |
|---|----|-----|----|--------------------------|
| 8. <u>End stage renal disease</u> (regardless of dialysis or transplantation)   | No | Yes | DK | <input type="checkbox"/> |
| 9. <b>OR</b> <input type="checkbox"/> Estimated or measured <u>GRF &lt; 50%</u> | No | Yes | DK | <input type="checkbox"/> |
| 10. <input type="checkbox"/> <u>Proteinuria &gt;= 3.5 gm/24 hours</u>           | No | Yes | DK | <input type="checkbox"/> |

**Pulmonary**

- |  |    |     |    |                          |
|--|----|-----|----|--------------------------|
| 11. <u>Pulmonary hypertension</u> by right ventricular prominence or loud P2 | No | Yes | DK | <input type="checkbox"/> |
| <u>Pulmonary fibrosis</u> by physical and x-ray                              | No | Yes | DK | <input type="checkbox"/> |
| <u>S</u> _____   | No | Yes | DK | <input type="checkbox"/> |
| <u>Pleural fibrosis</u> by x-ray   | No | Yes | DK | <input type="checkbox"/> |
| <u>F</u> _____   | No | Yes | DK | <input type="checkbox"/> |

**Cardiovascular**

- |  |    |     |        |                          |
|--|----|-----|--------|--------------------------|
| A _____  | No | Yes | DK     | <input type="checkbox"/> |
| 17. <u>Myocardial infarction</u> (documented by electrocardiograph and enzyme studies) | 0  | 1   | *2+ DK | <input type="checkbox"/> |
| C _____  | No | Yes | DK     | <input type="checkbox"/> |
| 19. <u>Valvular disease</u> (diastolic murmur or systolic murmur > 3/6)                | No | Yes | DK     | <input type="checkbox"/> |
| 20. <u>Pericarditis</u> for 6 months or <u>pericardiectomy</u>                         | No | Yes | DK     | <input type="checkbox"/> |

\* Circle 2 if more than 1 episode 6 months apart.

CLU ID#: «clu\_study\_id»

Office  
Use Only

**Peripheral Vascular**

(Please circle only one response)

- 21. Claudication for at least 6 months by history No Yes DK
- 22. Minor tissue loss (e.g., pulp space) No Yes DK
- 23. Significant tissue loss (e.g., digit or limb, or resection) 0 1 \*2+ DK
- 24. Venous thrombosis with swelling, ulceration or clinical evidence of venous stasis No Yes DK

**Gastrointestinal**

- 25. Infarction or resection of bowel (below duodenum), by history, resection of spleen, liver, or gall bladder for whatever cause 0 1 \*2+ DK
- 26. Mesenteric insufficiency with diffuse abdominal pain on clinical exam No Yes DK
- 27. Chronic peritonitis with persistent abdominal pain and peritoneal irritations on clinical exam No Yes DK
- 28. Esophageal stricture shown on endoscopy or upper GI tract surgery (e.g., correction of stricture, ulcer surgery) No Yes DK
- 29. Pancreatic insufficiency requiring enzyme replacement or with a pseudocyst No Yes DK

**Musculoskeletal**

- 30. Muscle atrophy or weakness, by clinical exam No Yes DK
- 31. Deforming or erosive arthritis (including reducible deformities, excluding avascular necrosis), by clinical exam No Yes DK
- 32. Osteoporosis with fracture or vertebral collapse (excluding avascular necrosis), demonstrated radiographically No Yes DK
- 33. Avascular necrosis, demonstrated by any imaging technique 0 1 \*2+ DK
- 34. Osteomyelitis, documented clinically and supported by culture evidence No Yes DK
- 35. Ruptured tendons No Yes DK

**Skin**

- 36. Alopecia (scarring, chronic, documented clinically) No Yes DK
- 37. Extensive scarring or panniculum other than scalp and pulp space, documented clinically No Yes DK
- 38. Skin ulceration (excluding thrombosis) for more than 6 months No Yes DK

**Other**

- 39. Premature gonadal failure, secondary amenorrhea, prior to age 40 No Yes DK
- 40. Diabetes requiring therapy, but regardless of treatment No Yes DK
- 41. Malignancy excluding dysplasia (documented by pathologic exam) 0 1 \*2+ DK

\* Circle 2 if more than 1 episode 6 months apart.

<b>FOR OFFICE USE ONLY</b>
SLE Cumulative Damage Score: <input style="width: 20px; height: 20px;" type="text"/> <input style="width: 20px; height: 20px;" type="text"/>

**Current Medications:**

**Dose:**

01.	
02.	
03.	
04.	
05.	
06.	
07.	
08.	
09.	
10.	
11.	
12.	
13.	
14.	
15.	
16.	
17.	
18.	


Please return each completed 4-page form in stamped, addressed envelope to:

Glinda Cooper, PhD, (NIEHS)  
National Institute of Environmental  
Health Sciences  
P.O. Box 12233  
Research Triangle Park, NC 27709

c/o Glenn Heartwell  
1-800-948-7552 x327  
Fax: (919)941-9349

